# US 2022/0031740 A1 · Therapeutic uses of atomic quantum clusters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031740 A1
- Document ID: US20220031740A1
- Status: Published application
- Kind: A1
- Application number: 17/280,051
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: Nanogap Sub-Nm-Powder, S.A.; Universidade De Santiago De Compostela
- Applicants: Nanogap Sub-Nm-Powder, S.A.; Universidade De Santiago De Compostela
- Inventors: David BUCETA FERNÁNDEZ; Fernando DOMÍNGUEZ PUENTE; Manuel Arturo LÓPEZ QUINTELA
- Web page: https://patentgrep.com/patent/US20220031740A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/28: Mercury; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 33/38: Silver; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- B22F 1/00: Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F 1/054: Nanosized particles
- C25C 1/12: of copper
- C25C 1/20: of noble metals
- C25C 5/02: from solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B22F: WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER (making alloys by powder metallurgy C22C); APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- C25C: PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR

## Abstract

There is provided an invention relating to compositions and therapeutic uses of atomic quantum clusters (AQCs), in particular compositions consisting essentially of AQCs comprising 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

## Claims

### Claim 1

A composition comprising atomic quantum clusters (AQCs) consisting of 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

### Claim 2 (depends on 1)

The composition for use according to claim 1, in combination with radiation therapy.

### Claim 3 (depends on 2)

The composition for use according to claim 2, for simultaneous or sequential administration to the radiation therapy.

### Claim 4 (depends on 2)

The composition for use according to claim 2, wherein the radiation therapy is external beam radiation therapy.

### Claim 5 (depends on 1)

The composition for use according to claim 1, wherein said composition is not used in combination with an antineoplastic drug.

### Claim 6 (depends on 1)

The composition for use according to claim 1, wherein said AQCs are the sole active ingredient of the composition.

### Claim 7 (depends on 1)

The composition for use according to claim 1, for use as a monochemotherapy.

### Claim 8 (depends on 1)

The composition for use according to claim 1, wherein the metal atoms are selected from Ag, Au, Cu, Pt, Fe, Cr, Pd, Ni, Rh, Pb, Ir, Ru, Os, Co, Ti, V or any combination thereof.

### Claim 9 (depends on 8)

The composition for use according to claim 8, wherein the metal atoms are selected from Ag, Au, Cu, Pt or any combination thereof.

### Claim 10 (depends on 8)

The composition for use according to claim 8, wherein the metal atoms are Ag.

### Claim 11 (depends on 1)

The composition for use according to claim 1, wherein the cell proliferative disorder is a tumour and/or cancer.

### Claim 12 (depends on 11)

The composition for use according to claim 11, wherein the cancer is selected from brain, lung, breast or colon cancer.

### Claim 13 (depends on 12)

The composition for use according to claim 12, wherein the cancer is selected from brain cancer.

### Claim 14 (depends on 1)

The composition for use according to claim 1, wherein the cell proliferative disorder comprises a RAS mutation.

### Claim 15 (depends on 14)

The composition for use according to claim 14, wherein the RAS mutation is a KRAS mutation.

### Claim 16 (depends on 1)

The composition for use according to claim 1, wherein the composition comprises a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 17 (depends on 1)

The composition for use according to claim 1, in combination with AQCs consisting of 3 zero-valent transition metal atoms.

### Claim 18 (depends on 1)

The composition for use according to claim 1, which is: (i) substantially free of AQCs consisting of more than 5 zero-valent transition metal atoms, (ii) substantially free of AQCs consisting of less than 5 zero-valent transition metal atoms, and/or (iii) substantially free of metal ions.

### Claim 19 (depends on 18)

The composition for use according to claim 18, wherein greater than about 95% of the AQCs present in the composition consist of 5 zero-valent transition metal atoms.

### Claim 20 (depends on 1)

The composition according to claim 1, for use in the prevention and/or treatment of metastasis of cancer.

### Claim 21 (depends on 20)

The composition according to claim 20, for use in the prevention and/or treatment of lymph node metastasis of cancer.

### Claim 22 (depends on 20)

The composition according to claim 20, for use in the prevention and/or treatment of metastasis of lung cancer.

### Claim 23 (depends on 1)

The composition for use according to claim 1, which is administered orally, intravenously or subcutaneously.

### Claim 24 (depends on 1)

Use of the composition according to claim 1, for the preparation of a pharmaceutical composition for the treatment of a cell proliferative disorder.

### Claim 25

Use of a composition comprising atomic quantum clusters (AQCs) consisting of 5 zero-valent transition metal atoms as a radiation therapy sensitizing agent for proliferating cells.

### Claim 26 (depends on 1)

A method of preventing or treating a cell proliferative disorder comprising administering a therapeutically effective amount of the composition according to claim 1, to a patient in need thereof.

### Claim 27

A method of preventing or treating a cell proliferative disorder comprising administering a therapeutically effective amount of a composition comprising atomic quantum clusters (AQCs) consisting of 5 zero-valent transition metal atoms, to a patient in need thereof, wherein said method does not comprise treating the patient with an additional antineoplastic drug.

### Claim 28

A method of preventing or treating a cell proliferative disorder comprising administering a therapeutically effective amount of a composition comprising atomic quantum clusters (AQCs) consisting of 5 zero-valent transition metal atoms, to a patient in need thereof, in combination with radiation therapy.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the composition is administered simultaneously or prior to the radiation therapy.

### Claim 30 (depends on 28)

The method according to claim 28, which comprises administering a therapeutically effective amount of a composition comprising AQCs consisting of 3 zero-valent transition metal atoms.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the composition comprising AQCs consisting of 3 zero-valent transition metal atoms is administered simultaneously or sequentially to the composition comprising AQCs consisting of 5 zero-valent transition metal atoms.

### Claim 32 (depends on 26)

The method according to claim 26, wherein the composition is administered orally, intravenously or subcutaneously.
